August 13, 2026: CIPHER-AXIS ranks legal interventions on a disease association graph
CIPHER-AXIS ranks the most justified protein or interaction to change for a disease, not only the gene most correlated with it.
CIPHERICA is extending its molecular compiler stack upstream of chemistry. CIPHER-SKI designs synthesizable small molecules through graph rewrites and statistical-mechanics ranking. CIPHER-AXIS applies the same idea to disease biology: it selects which protein or interaction to change before a molecule is made, so target choice is an explicit intervention, not only a correlation score.
June 12, 2026: We are proud to announce our acceptance into the NVIDIA Inception Program
This milestone provides CIPHERICA with access to NVIDIA’s world-class AI infrastructure, technical expertise, and hardware acceleration capabilities. By integrating these resources, we will significantly accelerate the development of our generative AI platform for molecular design, enabling faster discovery of novel, high-quality, and synthesizable therapeutic candidates.
June 3, 2026: CIPHERICA Files Patent for CIPHER-SKI: A “Molecular Compiler” for Drug Discovery
CIPHERICA has filed a foundational patent for CIPHER-SKI, a novel platform that applies compiler-inspired graph rewriting techniques to drug discovery. By treating molecules as programmable systems, CIPHER-SKI enables systematic, rule-based modification of molecular structures in a manner similar to how compilers optimize and transform code. This approach aims to bring the rigor and composability of modern compiler infrastructure to the design of new therapeutic molecules.